James E. Galvin, MD, MPHProfessor of Neurology
Chief, Cognitive Disorder Services Palm Beach
Director, Comprehensive Center for Brain Health
James E. Galvin, M.D., M.P.H. is a Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine. He is the Founding Director of the Comprehensive Center for Brain Health, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence, and Chief of Cognitive Neurology for Palm Beach and Broward County leading brain health and neurodegenerative disease research and clinical programs. Dr. Galvin has authored over 300 scientific publications and 3 textbooks on healthy brain aging, cognitive health, Alzheimer’s disease, Lewy Body dementia, and related disorders. Dr. Galvin has received over $100 Million in research funding from the National Institutes of Health, Alzheimer’s Association, Michael J Fox Foundation, American Federation for Aging Research, Lewy Body Dementia Association, Association for Frontotemporal Degeneration, Missouri, New York, and Florida Departments of Health, and numerous Private and Family Foundations.
The major focus of Dr. Galvin’s clinical and research career has been to improve the clinical care and quality of life for all older adults from diverse backgrounds and their family caregivers who are dealing with neurodegenerative disorders in order to initiate early intervention, alleviate psychosocial burden on the patient and family, reduce the impact of race, language, culture, and class on the delivery of health services, and improve health outcomes. His current research program focuses on four themes: (1) Developing and validating new clinical assessment scales to improve detection of cognitive impairment in multicultural community samples to improve health outcomes; (2) Studying the interaction between race, ethnicity, socioeconomic status, and multiple chronic conditions on the risk of cognitive impairment; (3) Characterizing the clinical, cognitive, behavioral, and biomarker features of neurodegenerative disorders; and (4) Creating novel precision-medicine based interventions based on individual phenotypic, biomarker, and genomic profiles aimed at ADRD risk reduction and dementia prevention.